Skip to content
April 23, 2024

Equity.Guru

Investment information for the new generation

Search

Core One Labs

Core One Labs (COOL.C) announced that their wholly-owned subsidiaries, Rejuva Mental Health Clinic and Bluejay Mental Health Group, have partnered to assist their patient with completing an application for…
Core One Labs’ (COOL.C) wholly-owned subsidiary Akome Biotech announced they are initiating the next step of their clinical development of their patent-pending psychedelic formulations AKO001 and AKO003. The next…
Core One Labs’ (COOL.C) wholly-owned subsidiary, Akome Biotech, has begun the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic…
Rollbacks Yesterday Core One Labs (COOL.C) announced an 8:1 share rollback to prepare itself for a Nasdaq listing. Today the company has 114,600,611 common shares outstanding, after the rollback,…
Core One Labs (COOL.C) announced that their wholly-owned subsidiary Vocan Biotechnologies are in the final stages of completing their provisional patent application for the protection of their proprietary biosynthetic…
Core One Labs (COOL.C) announced their wholly-owned subsidiary, Akome Biotech, has begun the development of its patent-pending psychedelic drug formulation for the treatment of Alzheimer’s Disease. Akome’s “next-generation” psychedelic…
Core One Labs (COOL.C) has completed the acquisition of Akome Biotech, a psychedelic-based pharmaceuticals company focused on providing effective and safe solutions to patients suffering from stroke and neurological…
Core One Labs (COOL.C) announced they have reached a definitive share purchase agreement which will see it acquire all outstanding share capital of Akome Biotech. Akome Biotech’s goal is…
Core One Labs (COOL.C) subsidiary, Vocan Biotechnologies, and the University of British Columbia (UBC), came to terms on a collaborative research agreement today, according to a press release. The…
Core One Labs’ (COOL.C) wholly-owned subsidiary Vocan Biotechnologies has initiated the design and engineering of a proprietary enzymatic production system for API-grade N,N-dimethyltryptamine, commonly known as DMT. DMT, also…